Holen Sie sich die Stockscreener-App
57.06
3.91%
-2.32
Handel nachbörslich:
57.06
Nektar Therapeutics Aktie (NKTR) Neueste Nachrichten
Nektar Therapeutics Director Roy Whitfield Reports Acquisition of RSUs and Stock Options - Kalkine Media
Form 4 Nektar Therapeutics For: 25 September By Investing.com - Investing.com Nigeria
Nektar Therapeutics (NKTR) grants a director 2,000 shares upon vesting and options to buy 4,000 more. - Stock Titan
A director receives 2,000 stock units alongside 4,000 options at Nektar Therapeutics (NKTR). - Stock Titan
Director Robert Chess also received 2,000 stock units from Nektar Therapeutics (NKTR), vesting in one year. - Stock Titan
Director Diana Brainard receives 2,000 stock units from Nektar Therapeutics (NKTR), vesting in one year. - Stock Titan
Nektar Therapeutics awarded $90 million in jury verdict against Eli Lilly By Investing.com - Investing.com South Africa
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says - reuters.com
Microsoft, Nike, Nektar Therapeutics - TradingView
Nektar Therapeutics Wins $90M Lilly Verdict - grafa.com
Nektar Therapeutics stock rises on $90M jury verdict vs Lilly - Investing.com
Lilly ordered to pay Nektar $90M in damages over rezpeg dispute - FirstWord
Jury awards Nektar Therapeutics $90M in rezpeg dispute with Eli Lilly - Dealroom
Nektar prevails in legal battle with Lilly over broken rezpeg partnership - BioSpace
Update: Nektar Wins $90 Million Jury Verdict Against Eli Lilly Over Rezpegaldesleukin Deal - Yahoo Finance
Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury FundsEli Lilly (NYS - Benzinga
BTIG reiterates Buy rating on Nektar Therapeutics, $178 price target - TradingView
Nektar Gets $90 Million Jury Award in Breach Suit Against Eli Lilly — Update - Morningstar
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data - Yahoo Finance
Why is Nektar Therapeutics stock climbing today? - Investing.com
Form 8K Nektar Therapeutics For: 25 September - Investing.com India
Form 8K Nektar Therapeutics For: 25 September By Investing.com - Investing.com Nigeria
Nektar Therapeutics awarded $90 million in jury verdict against Eli Lilly - Investing.com Canada
Nektar gains 5% as jury awards $90M plus interest in Lilly trial - TradingView
Nektar Therapeutics awarded $90M jury verdict against Eli Lilly over rezpegaldesleukin dispute - TradingView
Nektar TherapeuticsJury Finds Lilly Breached Implied Covenant Of Good Faith In License Agreement - TradingView
Eli Lilly Hit With $90M Verdict In Nektar's Rezpeg Breach Suit - Law360
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Nektar Therapeutics stock gains 2.98 percent on trial watch - ad-hoc-news.de
Wedbush maintains Neutral rating on Nektar Therapeutics, $50 price target - TradingView
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits
Nektar Therapeutics stock falls 9.6 percent as patent case weighs - ad-hoc-news.de
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Nektar Therapeutics drops as jury deliberates in Eli Lilly dispute over Rezpeg - TradingView
How Investors Are Reacting To Nektar Therapeutics (NKTR) Index Reclassification - simplywall.st
Nektar Therapeutics(NasdaqCM: NKTR) added to S&P Biotechnology Select Industry Index - marketscreener.com
Nektar Therapeutics(NasdaqCM:NKTR) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com
Nektar Therapeutics (NKTR), What Is Drawing Fresh Attention Now? - simplywall.st
Lilly Left Nektar Drug 'Damaged Goods,' Jury Told At Trial End - Law360
Nektar Therapeutics stock gains after Q2 loss narrows - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Investors to Connect - ACCESS Newswire
Nektar Therapeutics options flow shows bullish bets against a bearish tape - Investing.com
Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates - Eastern Progress
Lilly Owes Nektar $1B If It Breached Rezpeg Deal, Jury Told - Law360
Nektar CEO Opens Door To Finance Questions In Eli Lilly Trial - Law360
Nektar to Release 24-Week Off-Treatment Data for Rezpegaldesleukin in Alopecia Areata - The Clinical Trial Vanguard
Eli Lilly 'Sabotaged' Rezpeg's Development, Nektar Tells Jury - Law360
Lancet Phase 2b REZOLVE-AD Data Could Be A Game Changer For Nektar Therapeutics (NKTR) - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect - ACCESS Newswire
Nektar Therapeutics (NKTR) Lands Lancet Backing, Is The Upside Already Priced In? - simplywall.st
2026-09-06 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect | NDAQ:NKTR | Press Release - stockhouse.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Peer‑Reviewed REZOLVE‑AD Phase 2b Data Could Be A Game Changer For Nektar Therapeutics (NKTR) - simplywall.st
Is Nektar Therapeutics (NKTR) Undervalued As Lancet Data Supports Its Phase 3 Path? - simplywall.st
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):